Kids

• JULO Becomes First Fintech in Indonesia to Guarantee Instant 10-Minutes Disbursement

  

  JAKARTA,Indonesia,Dec. 10,2024-- JULO,Indonesia\'s leading fintech offering Virtual Credit Card features,has just raised the bar in digital financial services by launching a first-of-its-kind guarante

  12-11

  Details

• Stellantis and CATL to Invest Up to €4.1 Billion in Joint Venture for Large-Scale LFP Battery Plant in Spain

  

  Joint venture to build an all-new lithium iron phosphate (LFP) battery plant at Stellantis\' Zaragoza,Spain site

  12-11

  Details

• From Swipes to Connections: Cake Meet Simplifies Professional Networking

  

  HO CHI MINH CITY,Vietnam,Dec. 10,2024-- Cake Meet,developed by Cake,a Taiwan-originated Global Talent Platform with over 7M users,is revolutionizing professional networking across Asia.

  12-11

  Details

• Arcfra Partner Day 2024 Successfully Held in Seoul

  

  SEOUL,South Korea,Dec. 10,2024-- Arcfra Pte. Ltd. (hereinafter referred to as "Arcfra," arcfra.com),a leading innovator in cloud infrastructure and full-stack solutions,hosted its first even

  12-11

  Details

• Clarifai and Getty Images Announce Strategic Engagement to Make AI-Generated Images Available to Clarifai Customers

  

  Agreement Ensures AI-Generated Images Are Responsibly Sourced,Legally Protected,and Safe for Commercial Use

  12-11

  Details

• Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib

  

  ROCKVILLE,Md. and SUZHOU,China,Dec. 10,2024-- Ascentage Pharma (6855.HK),a global biopharmaceutical company engaged in discovering,developing,and commercializing therapies to address global unmet med

  12-11

  Details

• Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report

  

  ROCKVILLE,Md. and SUZHOU,China,Dec. 10,2024--Ascentage Pharma (6855.HK),a global biopharmaceutical company engaged in discovering,developing,and commercializing therapies to address global unmet medi

  12-11

  Details

• 【2024 ASH】TransThera Announces the Phase I Study Results of TT-01488, a Novel Non-Covalent BTK Inhibitor, in Patients with Relapsed or Refractory B-cell Malignancies

  

  NANJING,China and GAITHERSBURG,Md.,Dec. 10,2024--TransThera Sciences (Nanjing),Inc. (the "TransThera"),a clinical demand-oriented,registrational clinical stage biopharmaceutical company focu

  12-11

  Details

• Xinhua Silk Road: Climate investment and financing under spotlight at key conference held in S. China's Guangzhou Nansha

  

  BEIJING,Dec. 11,2024-- Guests from home and abroad shared experiences in climate investment and financing as well as reached consensus on addressing climate change on December 8 as they gathered in Na

  12-11

  Details

• Call for Application for 2025 Tsinghua Amgen Scholars Program

  

  BEIJING,Dec. 11,2024-- TheAmgen Scholars Program (ASP) is an international program funded by the Amgen Foundation with the direction of Harvard University,aiming to increase research opportunities for

  12-11

  Details